EE271 Cost-Effectiveness Analysis of RSVPreF3 OA Vaccine for Adults 60 Years or Older in Austria.

Autor:	Zarkadoulas, L1 (AUTHOR), Uhl, G2 (AUTHOR), Rouha, H2 (AUTHOR)
Zdroj:	Value in Health. 2024 Supplement, Vol. 27 Issue 12, pS106-S107. 2p.
Databáze:	Academic Search Ultimate
Externí odkaz:	Zobrazit plný text záznamu Full Text from ScienceDirect